STEPAN CO Q3 FY2026 earnings call

• Financial & Operational Performance: Adjusted EBITDA rose 18% to $66.3 million; adjusted EPS nearly doubled to $0.94. Consolidated organic volume grew 7% across all segments.
• Strategic Pillars: Strategy anchored in customer-centric innovation, market diversification (focus on Tier 2/3 accounts), operational excellence, and financial strength/deleveraging.
• Margin Recovery: Pricing actions and contractual pass-through mechanisms successfully offset volatile raw material costs and Middle East-related supply chain disruptions.
• Project Catalyst: Savings run rate reached ~$23 million in Q3. The company now expects to exceed the initial 60% ($100M) two-year savings target, aiming for $66-$70 million in 2026.
• Balance Sheet & Cash Flow: Net leverage improved to 2.4x from 2.7x. Free cash flow was positive at $8 million despite working capital headwinds. Land sale proceeds of $28.5 million used for debt reduction.
• Regional Highlights: North America polymers showed strong double-digit growth. Latin America benefited from local production advantages against Asian imports. Europe faced macro headwinds but has pent-up demand potential.

• Surfactants: Net sales of $487 million (up 15% YoY); Adjusted EBITDA of $48 million (up 27% YoY). Organic volume grew 8%, driven by consumer products, oil field, and construction/industrial markets. Revenue contribution was approximately 73.6% of total segment sales ($487M / $663M).
• Polymers: Net sales of $179 million (up 24% YoY); Adjusted EBITDA of $23 million (up 4% YoY). Organic volume grew 3%, with strong double-digit growth in North America rigid polyols and spray foam, offset by maintenance costs at the Germany site and soft demand in Europe/Asia. Revenue contribution was approximately 27.0% of total segment sales.
• Specialty Products: Net sales of $27 million (up 12% YoY); Adjusted EBITDA of $11.7 million (up 5% YoY). Organic volume surged 20%, led by the MCT product line. Revenue contribution was approximately 4.1% of total segment sales.

• 2026 Full Year Outlook: Management expects to deliver full-year adjusted EBITDA growth, positive free cash flow, and continued balance sheet deleveraging.
• Project Catalyst Savings: Revised upward expectation for 2026 savings to the $66–70 million range, exceeding the original $100 million two-year target trajectory.
• Long-term Run Rate: Project Catalyst is projected to achieve an average quarterly savings run rate of >$25 million in 2027, implying incremental gains over current levels.
• Dividend: Quarterly dividend increased by $0.01 per share (2.5%), marking the 59th consecutive year of increases.

• Macroeconomic Volatility: Ongoing global economic uncertainties and regional slowdowns, particularly in Europe and China's auto/construction sectors.
• Geopolitical Disruption: Middle East conflict impacting fixed costs and supply chain stability.
• Raw Material Inflation: Continued volatility in oil prices and feedstock costs, requiring constant pricing adjustments.
• Agricultural Market Weakness: Softening crop productivity demand due to broader ag industry struggles and fertilizer price pressures.
• Regulatory Costs: Mandated five-year maintenance turnarounds at the Germany site causing temporary EBITDA headwinds.

Q: Analyst asked about margin pressure from raw material inflation and when pricing will fully neutralize higher costs.

A: CEO stated margins are healthy (Surfactants double-digit, Polymers 13-15%) and most price adjustments for Q3 oil levels are complete. While some volatility remains, the commercial team has effectively balanced volumes and margins, with YTD organic volume growth near record levels. He emphasized that while Q4 may see lower growth due to Q2/Q3 pre-buying effects, the overall strategy focuses on keeping reactors full while maintaining value for customers.

Q: Analyst queried if Project Catalyst savings would remain at $40 million incremental for 2027 or if they could be higher.

A: CEO confirmed savings are ahead of plan, targeting $66-$70 million for 2026 instead of the initial 60% target. For 2027, he expects the average quarterly run rate to exceed $25 million, adding $2-3 million more than current levels. This gradual increase reflects ramping up new facilities like Pasadena and implementing pipeline projects, separate from normal inflationary impacts on the fixed cost base.

Q: Analyst asked about green shoots in weak European and Asian polymer markets and the impact of El Niño on ag volumes.

A: CEO attributed weakness to macro factors, specifically China’s auto industry and Europe’s construction/energy challenges, but noted significant pent-up demand for building envelope insulation solutions over the next 3-5 years. Regarding agriculture, he acknowledged sector struggles but highlighted Stepan’s success in tank mix adjuvants through innovation and capturing share among Tier 2/3 ag companies, viewing this as a key strategic priority despite unfavorable macro conditions.

Q: Analyst questioned the sustainability of MCT specialty product growth and Pasadena utilization rates.

A: CEO explained that MCT growth is driven by expanded offerings into mid-tier price segments and pharma seasonality, though fatty acid pricing headwinds limited faster growth. He noted Pasadena is operating at 75-80% utilization, focusing on maximizing dollar return per reactor hour rather than pure volume. The team anticipates further tolling savings in H2 2027 as production ramps up, ensuring capacity is filled at profitable margins.

Q: Analyst asked about Latin America exposure to Asian imports and the structural nature of its recovery.

A: CEO highlighted that local production provides a significant advantage, especially in Mexico where Asian imports are prevalent, while Brazil remains protected. He praised the Brazil team’s outstanding performance and affirmed that growth in LatAm is sustainable. The strategy involves continuing to grow share and fill reactors at appropriate margins, leveraging the regional footprint to provide value against import competition.